GlassScriptPhysician profile
Ann M Kledzik
NPI 1790989671
$12,101.18
in general payments reported to CMS, 2019-2025
33 companies · $2,297 in 2025
The $2,297 reported for 2025 was more than what 95% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $850 · 2020: $786 · 2021: $1,362 · 2022: $2,159 · 2023: $2,253 · 2024: $2,394 · 2025: $2,297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,937 · Education: $7.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,936.85 |
| Education | $7.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $1,716.76 | 2021-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $1,694.76 | 2019-2025 | Spravato |
| Abbvie INC. | $1,285.14 | 2021-2025 | |
| Ironshore Pharmaceuticals INC. | $821.28 | 2019-2024 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $654.93 | 2020-2025 | Caplyta |
| Bausch Health US, LLC | $642.97 | 2019-2025 | Aplenzin, Wellbutrin |
| Otsuka America Pharmaceutical, INC. | $614.10 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Neos Therapeutics, LP | $587.80 | 2019-2025 | Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $459.99 | 2019-2025 | Trintellix |
| Corium, LLC | $441.96 | 2021-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $409.24 | 2021-2025 | Fanapt, Hetlioz |
| Tris Pharma INC | $358.34 | 2019-2025 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $336.22 | 2022-2025 | Auvelity, Sunosi |
| Noven Therapeutics, LLC | $328.03 | 2023-2025 | Xelstrym, Secuado |
| Lundbeck LLC | $236.25 | 2019-2025 | Rexulti |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $206.55 | 2022-2025 | Ingrezza |
| Allergan, INC. | $194.64 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $192.27 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $148.51 | 2019-2023 | Belsomra |
| Alkermes, INC. | $136.61 | 2021-2023 | Aristada, Lybalvi |
| Adlon Therapeutics L.P. | $130.66 | 2019-2021 | |
| Eisai INC. | $93.32 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $80.11 | 2022-2025 | Austedo Xr, Austedo Xr |
| Vertical Pharmaceuticals, LLC | $74.64 | 2019-2025 | Relexxii |
| Idorsia Pharmaceuticals US INC | $49.70 | 2022-2023 | Quviviq |
| Rhodes Pharmaceuticals L.P. | $41.91 | 2019 | |
| Owp Pharmaceuticals, INC. | $40.60 | 2023-2025 | Subvenite, Lamotrigine |
| Brainsway USA INC | $32.31 | 2021 | |
| Neuronetics, INC. | $29.69 | 2023 | Neurostar Tms Therapy System |
| Sunovion Pharmaceuticals INC. | $16.86 | 2019 | |
| Almatica Pharma LLC | $16.64 | 2024 | Loreev Xr |
| Alfasigma USA, INC. | $14.32 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Kledzik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.